Research map: Immune checkpoint inhibitor-induced cardiotoxicity: from immune mechanisms to clinical surveillance and targeted therapies

Back to the article

Papers in this map

  1. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma · Richard S. Finn · 2020 · 7562 citations · Cited by this paper
  2. Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study · Yanxin Chen · 2025 · 13 citations · Related
  3. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion · Haidong Dong · 2002 · 5117 citations · Cited by this paper
  4. High density lipoproteins and extracellular vesicles—distinct but overlapping circulating particles and their role in atherosclerosis · 2026 · Related
  5. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline · Julie Renee Brahmer · 2018 · 3767 citations · Cited by this paper
  6. In-hospital inflammatory-nutritional-renal trajectory phenotypes and 90-day readmission or mortality in patients with acute decompensated heart failure: a retrospective cohort study · 2026 · Related
  7. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression · Chih‐Hao Chang · 2015 · 3398 citations · Cited by this paper
  8. Comparative associations and incremental predictive value of cardiometabolic and inflammatory indices for short- to mid-term cardiovascular disease risk in two Chinese cohorts · 2026 · Related
  9. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade · Yoshiko Iwai · 2002 · 3256 citations · Cited by this paper
  10. Immune checkpoint inhibitor–induced myocarditis is dependent on CD8 T cell–derived TNF and TNFR2 signaling · 2026 · Related
  11. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) · Alexander Richard Lyon · 2022 · 3064 citations · Cited by this paper
  12. Growth differentiation factor 15 level changes in the early and late periods after radiofrequency and pulsed field catheter ablation of atrial fibrillation · 2026 · Related
  13. CTLA-4 Control over Foxp3 + Regulatory T Cell Function · Kajsa Wing · 2008 · 2949 citations · Cited by this paper
  14. Single-cell RNA sequencing pseudobulk analysis and machine learning identify candidate biomarkers for ischemic cardiomyopathy · 2026 · Related
  15. The cGAS–STING pathway as a therapeutic target in inflammatory diseases · Alexiane C. Decout · 2021 · 2342 citations · Cited by this paper
  16. Proactive Surveillance for ICI Cardiotoxicity · 2026 · Related
  17. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance · Filipe Martins · 2019 · 2339 citations · Cited by this paper
  18. Tocilizumab in immune checkpoint inhibitor-induced myositis, myocarditis, and myasthenic syndrome: a rare case report and review of the literature · 2025 · Related
  19. Fulminant Myocarditis with Combination Immune Checkpoint Blockade · Douglas Buckner Johnson · 2016 · 2337 citations · Cited by this paper
  20. Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting system · 2026 · Related
  21. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update · Bryan J. Schneider · 2021 · 2223 citations · Cited by this paper
  22. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation · Vanessa M. Ferreira · 2018 · 2064 citations · Cited by this paper
  23. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells · Dmitry I. Gabrilovich · 1996 · 1995 citations · Cited by this paper
  24. CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms · Richard V. Parry · 2005 · 1952 citations · Cited by this paper
  25. Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4 · Omar Qureshi · 2011 · 1862 citations · Cited by this paper
  26. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study · Jong‐Mu Sun · 2021 · 1681 citations · Cited by this paper
  27. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors · Syed Amer Mahmood · 2018 · 1605 citations · Cited by this paper
  28. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines · Salim S. Virani · 2023 · 1551 citations · Cited by this paper
  29. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study · Joe‐Elie Salem · 2018 · 1266 citations · Cited by this paper
  30. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors · Thibault Voron · 2015 · 1194 citations · Cited by this paper
  31. Pathophysiology of Atherosclerosis · Shifa Jebari‐Benslaiman · 2022 · 1008 citations · Cited by this paper
  32. BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma · Dennie Tompers Frederick · 2013 · 964 citations · Cited by this paper
  33. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection · Constantinos Petrovas · 2006 · 889 citations · Cited by this paper
  34. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4 · Hye Sun Kuehn · 2014 · 866 citations · Cited by this paper
  35. Distinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart · Kory J. Lavine · 2014 · 831 citations · Cited by this paper
  36. Cardiotoxicity of Chemotherapeutic Agents · Vinita B. Pai · 2000 · 735 citations · Cited by this paper
  37. The caspase-3/GSDME signal pathway as a switch between apoptosis and pyroptosis in cancer · Mingxia Jiang · 2020 · 702 citations · Cited by this paper
  38. The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease · Leslie T. Cooper · 2007 · 677 citations · Cited by this paper
  39. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial · Ralf Gutzmer · 2020 · 673 citations · Cited by this paper

Source: OpenAlex (CC0)